ISEV

Mursla Bio Unlocks New Biomarker Discovery Approach in Liquid Biopsy and Precision Medicine

Retrieved on: 
Tuesday, May 16, 2023
Professional Services, Health, Medical Devices, Health Technology, Finance, Pharmaceutical, Biotechnology, Tissue, Red, EV, WHO model list of essential in vitro diagnostics, Workflow, Hepatocellular carcinoma, Bio, Liquid biopsy, Cancer, Extracellular vesicle, Biomarker, Doctor of Philosophy, Lung, Trial of the century, EVS, Liver cancer, Plasma, Seminal vesicles, ISEV, Patient, Blood, Medicine, Kidney, Liver, International Society for Extracellular Vesicles, Poster, HCC, International Society, Conditional sentence, Disease, Medical imaging, Vaccine, Fireworks

Mursla Bio will present its novel tissue-specific Extracellular Vesicle (EV) isolation technology, NEXPLOR, at the International Society for Extracellular Vesicles (ISEV) annual meeting, paving the way for a new approach to biomarker discovery in liquid biopsy and precision medicine.

Key Points: 
  • Mursla Bio will present its novel tissue-specific Extracellular Vesicle (EV) isolation technology, NEXPLOR, at the International Society for Extracellular Vesicles (ISEV) annual meeting, paving the way for a new approach to biomarker discovery in liquid biopsy and precision medicine.
  • Conventional isolation techniques cannot distinguish between EVs based on their origin, thus limiting progress in disease biomarker discovery.
  • Dr Tomás Dias (PhD), CTO, Mursla Bio commented: “NEXPLOR can isolate specific sub-populations of EVs, such as liver-specific EVs, from complex fluids like blood.
  • This is an important step forward to develop EV-based liquid biopsy and precision medicine applications.”
    NEXPLOR is part of Mursla Bio’s ExoPheno™ platform and has been engineered to improve the translation of EV-based diagnostics into clinics.

Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics

Retrieved on: 
Friday, May 12, 2023
Tissue, Single, Central nervous system, EV, Gene, Intrinsic termination, Exosome, Onto Innovation, Cell, RNA, Quantification, CNS, Messenger, Small RNA, Seminal vesicles, Flow cytometry, Animal, ISEV, Buffer, Annual general meeting, American Society of Gene and Cell Therapy, RNA interference, International Society for Extracellular Vesicles, LNP, Therapy, Society, International Society, Vaccine

The six oral presentations and posters highlight the progress made in leveraging the versatility of the Company’s DeliverEX® exosome platform to deliver a wide range of genetic medicines ranging from genome editors, RNAi and mRNA as well as presenting on other exosome-related advances.

Key Points: 
  • The six oral presentations and posters highlight the progress made in leveraging the versatility of the Company’s DeliverEX® exosome platform to deliver a wide range of genetic medicines ranging from genome editors, RNAi and mRNA as well as presenting on other exosome-related advances.
  • Exosome delivery to the CNS (oral presentation): Gupta et al., provide an overview of the ability to engineer exosomes to express any desired therapeutic, including genome editors.
  • In vivo rodent data demonstrated a high degree of gene recombination after direct CNS injection using Evox’s proprietary exosome drug loading and release technology.
  • Development of exogenous loading platforms for functional targeted EV-mediated siRNA therapeutics delivery (PF09.09; poster): Levitin et al., report on progress loading of siRNA into/onto exosomes and demonstrate functional silencing activity of exosome-delivered siRNA.

Mercy BioAnalytics Raises $41 Million in Series A Financing to Advance Novel Mercy Halo Liquid Biopsy Platform for Early Cancer Detection

Retrieved on: 
Monday, April 3, 2023
Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Other Health, DNA, AACR, International Society for Extracellular Vesicles, Serum, Survival, American Society of Clinical Oncology, Cancer, Lung cancer, Doctor of Philosophy, II, Novalis, ASCO, Plasma, Seminal vesicles, ISEV, American Association for Cancer Research, Data, Mercy, American Cancer Society, Ovarian cancer, Labcorp, Society, Conference, International Society, Biopsy, Vaccine, Medical imaging, Bruker

Mercy BioAnalytics, Inc. , a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced it has closed a $41 million Series A financing round.

Key Points: 
  • Mercy BioAnalytics, Inc. , a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced it has closed a $41 million Series A financing round.
  • The company’s novel Mercy Halo™ platform unlocks high clinical sensitivity and specificity through the simultaneous detection of multiple cancer-related biomarkers co-localized on the surface of individual tumor-derived extracellular vesicles.
  • Proceeds from the financing will be used to advance development and commercialization of the Mercy Halo test for high-risk lung cancer screening, the company’s lead clinical indication.
  • Mercy intends to leverage its Mercy Halo liquid biopsy platform technology to develop a broad portfolio of tests for the early detection of cancer.

ExoCoBio's First Global Regenerative Aesthetic Exosome Summit

Retrieved on: 
Tuesday, August 16, 2022
Multimedia, LG Chem, Inflammatory bowel disease, CEO, Technology, USD, Cosmetics, Scalp, Research, KRW, Acute respiratory distress syndrome, Cell, Aesthetic Surgery Journal, Therapy, Skin, GMP, Exosome, Cosmeceutical, ISEV, Journal of Extracellular Vesicles, Atopic dermatitis, International Society, Journal, Summit, International Society for Extracellular Vesicles, Endoplasmic reticulum, Seminal vesicles, Medical device, Pharmaceutical industry

SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18.

Key Points: 
  • SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18.
  • ExoCoBio will share the significant results of clinical cases of applying ASCE+, regenerative aesthetic product developed by ExoCoBio's manufacturing technology, ExoSCRT for high-efficient and high-purity exosome, to skin and scalp.
  • At this Summit, in particular, Dr. Jan Lotvall and Dr. Sai Kiang Lim, two of the world's best exosome researchers will be invited to present the latest exosome science and interact with attendees.
  • He also said, "In the long run, this Summit will grow into a global platform for exosome industrialization."

ExoCoBio's First Global Regenerative Aesthetic Exosome Summit

Retrieved on: 
Tuesday, August 16, 2022
LG Chem, Inflammatory bowel disease, CEO, Technology, USD, Cosmetics, Scalp, Research, KRW, Acute respiratory distress syndrome, Cell, Aesthetic Surgery Journal, Therapy, Skin, GMP, Exosome, Cosmeceutical, ISEV, Journal of Extracellular Vesicles, Atopic dermatitis, International Society, Journal, Summit, International Society for Extracellular Vesicles, Endoplasmic reticulum, Seminal vesicles, Medical device, Pharmaceutical industry

SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18.

Key Points: 
  • SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCoBio will hold the world first "Regenerative Aesthetic Exosome Summit 2022" (hereinafter the "Summit") under the topic of exosomes at the Marriott Hotel Dongdaemun on September 17~18.
  • ExoCoBio will share the significant results of clinical cases of applying ASCE+, regenerative aesthetic product developed by ExoCoBio's manufacturing technology, ExoSCRT for high-efficient and high-purity exosome, to skin and scalp.
  • At this Summit, in particular, Dr. Jan Lotvall and Dr. Sai Kiang Lim, two of the world's best exosome researchers will be invited to present the latest exosome science and interact with attendees.
  • He also said, "In the long run, this Summit will grow into a global platform for exosome industrialization."

CELLS for CELLS treats the first-ever patient with an exosome-produced therapy for osteoarthritis

Retrieved on: 
Monday, July 18, 2022
R, Business, IP, Patient, Arthropathy, Safety, Longevity, Therapy, Osteoarthritis, Quality of life, GLOBE, II, Cartilage, NewCo, Exosome, ISEV, Business development, Clinical data repository, ISCT, Associate, MSC, WOMAC, Seminal vesicles, Stem cell, FDA, Achievement, SAN, Pharmaceutical industry, C4C, Cell

The results were made public at an extracellular vesicles signature series during the ISCT annual meeting in San Francisco and the ISEV meeting in Lyon, France.

Key Points: 
  • The results were made public at an extracellular vesicles signature series during the ISCT annual meeting in San Francisco and the ISEV meeting in Lyon, France.
  • Dr. Maroun Khoury, Chief Scientific Officer of C4C, presented the results of the first trial evaluating the safety and efficacy of exosome biotherapeutics in joint disease.
  • This study reported an unprecedented WOMAC score reduction six months after a single administration of XO-101, C4C's flagship exosome therapy derived from mesenchymal stem cells (MSC).
  • Following this success, Cells for Cells decided to spin out its exosome asset into a new US-based company focusing on well-aging and longevity.

Evox Therapeutics Presents Progress Across its DeliverEX™ Exosome Therapeutics Platform with Nine Presentations at the International Society for Extracellular Vesicles (ISEV) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Doxorubicin, PBS, Organic acid, Lysosomal storage disease, Engineering, Transferrin, Company, International Society, Spleen, ISEV, Neoplasm, International Society for Extracellular Vesicles, ERT, Seminal vesicles, Endothelium, Ligand, Inflammation, Antibody, Therapy, E-selectin, Exosome, GAA, Half-life, Liver, Degenerative disease, Comparison, ABS, Neutralizing antibody, Cell, Cell biology, Mouse, Glycogen storage disease type II, CNS, Brain, Plasma, EVS, BBB, FC, RNA, Central nervous system, Technology, South Luzon Expressway, Enzyme replacement therapy, Trehalose, Protein, Oxford, GLOBE, Tissue, Muscle, Pharmaceutical industry, Wood drying, Vaccine, Fine chemical

In parallel, we are also focused on advances in exosome manufacturing, including exploring new ways to produce exosome therapeutics.

Key Points: 
  • In parallel, we are also focused on advances in exosome manufacturing, including exploring new ways to produce exosome therapeutics.
  • We believe our advances will allow exosome therapeutics access to cellular compartments and tissues that are currently out of reach using other approaches.
  • This could provide significant benefit for both creating feasible dosing regimens and to ensure sufficient plasma residence time for tissue-specific targeting.
  • Engineered display of ligands on the surface of exosomes can be used to increase specific targeting of exosomes to desired tissues.

BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, May 16, 2022
Senior, Medical Affairs Bureau, MHSC, ISCT, American Academy, Exo, International Society, Master of Science, ISEV, Drug development, Research, VP, NEW, Hospital, Doctor of Philosophy, Clinical, Company, Webcast, Patient, NASDAQ, ADV, Therapy, Episcopal conference, MPH, Adult, Antal, Neurology, Neurodegeneration, Cerebrospinal fluid, Conference, Conference call, Neuroprotection, Congress, Biomarker, HIV disease progression rates, Proning, Division, Massachusetts General Hospital, Harvard Medical School, Muscular dystrophy, Growth, Development, ALS, Management, Pharmaceutical industry, Medical device, Online gambling, MD

NEW YORK, May 16, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Key Points: 
  • The presentation was delivered by Dr.Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.
  • Announced upcoming presentations at the ALS Drug Development Summit (May 25, 2022) and the ISEV 2022 Annual Meeting (May 26, 2022).
  • Presented a corporate and Phase 3 ALS clinical overview at the 12thAnnual California ALS Research Summit on January 27, 2022 by Ralph Kern MD MHSc, President and Chief Medical Officer Brainstorm Cell Therapeutics.
  • Net loss per share for the three months ended March 31, 2022, and 2021 was $0.15 and $0.19 respectively.

International Society for Cell & Gene Therapy Presentations Illustrate Evox Therapeutics’ Proprietary Exosome Engineering Platform with New Data on Exosome Targeting and In Vivo Distribution

Retrieved on: 
Monday, May 9, 2022
Brain, Karolinska Institute, Exosome, GLOBE, RNA, Engineering, Oxford, Cell, ISCT, Degenerative disease, Delivery, Gene editing, Therapy, EVS, Tissue, ISEV, Science, Technology, International Society, Neoplasm, Seminal vesicles, Central nervous system, Medical device

OXFORD, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy (ISCT) 2022 Meeting, May 4 to 7, in San Francisco.

Key Points: 
  • OXFORD, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy (ISCT) 2022 Meeting, May 4 to 7, in San Francisco.
  • The presentations were part of the ISCT 1-day Scientific Signature series Therapeutic Advances with Native and Engineered Human EVs.
  • Samir El Andaloussi, Ph.D., Evox co-founder and Professor at the Karolinska Institut, presented on EV Engineering for Directed Loading and Delivery of Biotherapeutics.
  • Evox is backed by leading life sciences venture capital groups including Redmile and Orbimed, and is supported by a comprehensive intellectual property portfolio.

BrainStorm Announces Upcoming Scientific Conference Presentations

Retrieved on: 
Tuesday, May 3, 2022
COVID-19, Amyotrophic lateral sclerosis, California Institute for Regenerative Medicine, National, Senior, EMA, Drug development, NASDAQ, Multiple sclerosis, European Medicines Agency, Company, Proning, MS, Biomarker, Food, Safety, Annual report, Regenerative medicine, CSF, Exo, ISCT, Neurodegeneration, Clinical trial, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Orphan drug, Transfusion-related acute lung injury, ISEV, Medical Affairs Bureau, Phrase, CIRM, Research, Pharmaceutical industry, Brainstorm, ALS

NEW YORK, May 3, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022.  New data on the company's proprietary MSC-NTF exosome technology will be presented at ISCT 2022 (May 4 to 7 in San Francisco, CA) and at the ISEV 2022 Annual Meeting (May 25 to 29 in Lyon, France).   An analysis of CSF biomarkers from the NurOwn® Phase 3 trial will be presented at the ALS Drug Development Summit (May 24 to 26 in Boston, MA).

Key Points: 
  • NEW YORK, May 3, 2022 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022.
  • An analysis of CSF biomarkers from the NurOwn Phase 3 trial will be presented at the ALS Drug Development Summit (May 24 to 26 in Boston, MA).
  • BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.